IW 338

February 1, 2026 Viktor Zarev 0 min read
  1. Confusion reigns over last-minute deal to avoid government shutdown. 
  2. U.S. life expectancy rebounds to hit all-time high.
  3. How are hospital executives getting ready for 2026?
  4. The most important healthcare trends to watch in 2026.
  5. Health systems call for better oversight of patient data-sharing.
  6. CMS working on smoother rollout of Medicaid work requirements.
  7. CMS officials defend decision not to raise MA payment rates.
  8. HCA warns of $1B revenue drop due to ACA subsidy lapse.
  9. FDA updates rules on medical device inspections.
  10. Federal research funding cuts impact first-year PhD students.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals February 9, 2026

Statin Side Effects Might Not be So Bad February 9, 2026

New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 the drugs’ package-listed adverse effects lack reliable evidence. In an attempt to clear statins’ name, researchers analyzed data from 19 large RCTs to distinguish real statin-associated risks from […]

Cardiology Business February 5, 2026

Medtronic Acquires CathWorks, Expands Cath Lab Presence February 5, 2026

Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition rights on AI FFR specialist, CathWorks, for $585M up-front. Until now CathWorks’ FFRangio has only been available in the U.S., Europe, and Japan through Medtronic’s distribution network, but […]

Cardiology Pharmaceuticals February 2, 2026

CKM’s True Medication Burden February 2, 2026

As cardiology begins to look at the spectrum of cardiovascular-kidney-metabolic disease, new research in JAMA suggests that CKM treatments might face serious adoption challenges due to the sheer number of Americans who both have the disease and qualify for medications. In a search for just how many eligible patients are out there, researchers examined FDA-approved […]